Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpelisib, LJM716, and Trastuzumab in Metastatic HER2+ Breast Cancer
NCT02167854Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2014
- Primary completion
- Jul 2021
- Countries
- 1
01
Overview
Phase 1, open-label trial of alpelisib in HER2-positive metastatic breast cancer, sponsored by Memorial Sloan Kettering Cancer Center. Started Jun 2014; status: completed.
02
Drugs
alpelisib
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT02167854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02167854.